RTTNews | Jan 5, 2022 07:13AM EST

07:13 Wednesday, January 5, 2022 (RTTNews.com) - Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced a research, development and commercialization collaboration to develop a mRNA-based vaccine for the prevention of shingles. The companies will leverage an antigen technology identified by Pfizer's scientists and BioNTech's mRNA platform technology used in the companies' COVID-19 vaccine. Clinical trials are planned to start in the second half of 2022.

Pfizer will pay BioNTech $225 million in upfront payments, including a cash payment of $75 million and an equity investment of $150 million. BioNTech is eligible to receive future regulatory and sales milestone payments of up to $200 million. BioNTech will pay Pfizer $25 million for the antigen technology.

Pfizer will have rights to commercialize the potential vaccine on a global basis, with the exception of Germany, Turkey and certain developing countries where BioNTech will have commercialization rights.

Read the original article on RTTNews ( https://www.rttnews.com/3252910/pfizer-biontech-join-to-develop-mrna-based-vaccine-against-shingles-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2022 RTTNews.com All Rights Reserved